Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial
Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial
Rapport Therapeutics
NASDAQ: RAPP $25.93 USD
Clinical-stage biopharmaceutical company developing precision small-molecule medicines that target receptor-associated proteins (RAPs) to treat central nervous system disorders, with lead programs in epilepsy.
Company Info
Sector:Biotechnology — CNS / Neurology
Headquarters:Boston, Massachusetts, United States
Founded:2022
Website:www.rapportrx.com/
Recent News
Leadership Team
Abraham Ceesay
President and Chief Executive Officer
Troy Ignelzi
Chief Financial Officer
Brian Corcoran
Chief Legal Officer